- AOD-9604 is a modified fragment derived from the C-terminal region of human growth hormone, studied in research settings for its relationship to lipolytic (fat-metabolism) signaling.
- The human evidence base for AOD-9604 is limited, and no controlled human trials in women have been indexed, so its female-specific record is effectively absent.
- Because fat metabolism is itself shaped by sex hormones and shifts across the menstrual cycle and menopause, the missing female data is a meaningful gap rather than a formality.
AOD-9604 arrives with a lot of fat-loss reputation and comparatively little published data behind it, and almost none of that data is about women. It is a modified peptide fragment derived from the C-terminal region of human growth hormone, isolated specifically to study the part of the molecule associated with fat-metabolism signaling rather than the full growth-promoting activity of the parent hormone. As a research material, that focus is its whole point.
What the fragment is designed to isolate
Full-length growth hormone influences many systems at once. AOD-9604 was developed to separate out the lipolytic, or fat-mobilizing, signaling associated with growth hormone's C-terminal region from its broader metabolic and growth effects. In research settings it has been studied for that lipolytic relationship in preclinical and early investigational models. It is handled here as a research compound, and its human record is limited.
The female record: absent or pending
This is the honest bottom line. No controlled human trials in women have been indexed for AOD-9604, and the female-specific fields are not populated with real findings. There is no cycle-phase data, no pregnancy or lactation safety data, and no menopausal data. On this site that state is reported as absent or pending, and it is deliberately not filled in with extrapolation from the general or preclinical literature.
Fat metabolism is shaped by sex hormones and shifts across the menstrual cycle and the menopausal transition. That makes it exactly the kind of area where borrowing male or mixed-population data to describe women would be misleading. For AOD-9604, the accurate statement is that the female-specific evidence has not been established.
Reading fat-loss fragment claims
AOD-9604 is marketed with confident weight and fat language. The research supports a narrower statement: it is a growth-hormone fragment studied for lipolytic signaling, with a limited human record. "Studied for" is the correct verb, not "burns fat" or "works." And for women specifically, even that cautious framing runs into the absence of sex-reported data. The current evidence state is tracked on the AOD-9604 profile, where the female-angle fields are marked pending rather than guessed.